News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: semper post# 190048

Saturday, 09/13/2014 1:09:06 PM

Saturday, September 13, 2014 1:09:06 PM

Post# of 347009

I spoke with my sister at length last night. She just retired from Bayer after a long career in the field of oncology. She also worked for Onyx Pharmaceuticals and Wyeth Pharmaceuticals. To sum our conversation up she believes Bavituximab will get approval and I'm just going to leave it at that. GLTA



nice post semper. That line of thought follows mine and believing Bavituximab will gain approval. The anti-PS platform of technoglogies just may send shivers globally, family/friends and I guess you could say everyone would naturally want a treatment that has Bavituximab.

Bavituximab is the part of that paradigm shifting key that unlocks the immune system, takes the brake off I hear often and to gain full traction and how do many other drugs accomplish this? I'll just say its sort of like driving with the emergency brake on and you are not getting very far before damage is done.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y